Vagus Nerve Stimulation Market Report 2026

The vagus nerve stimulation market size has grown rapidly in recent years. It will grow from $1.02 billion in 2025 to $1.17 billion in 2026 at a compound annual growth rate (CAGR) of 14.9%. The growth in the historic period can be attributed to increasing prevalence of epilepsy and depression, expansion of neuromodulation research, availability of implantable stimulation technologies, rising awareness of alternative neurological therapies, growth of specialty neurology clinics.

The vagus nerve stimulation market size is expected to see rapid growth in the next few years. It will grow to $2.02 billion in 2030 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to increasing demand for personalized neuromodulation therapies, rising adoption of wearable medical devices, expansion of neurological disorder treatment options, growing focus on non-pharmacological interventions, ongoing innovation in stimulation technologies. Major trends in the forecast period include increasing adoption of non-invasive vns devices, rising use of vns in depression management, growing integration of wearable neuromodulation technologies, expansion of home-based neuromodulation therapies, enhanced focus on patient-specific stimulation protocols.

The growing incidence of neurological disorders is anticipated to drive the expansion of the vagus nerve stimulation market in the coming years. Neurological disorders refer to conditions affecting the brain, spinal cord, or nerves, often resulting in impairments related to movement, sensation, cognition, or overall bodily function. These disorders arise from a wide range of causes, including genetic predisposition, environmental exposure, and lifestyle-related factors. Moreover, traumatic events such as head injuries or spinal cord damage can also contribute to neurological complications. Vagus nerve stimulation is widely used in managing such conditions as it helps regulate brain activity and neurotransmitter levels, thereby alleviating symptoms associated with epilepsy, depression, and certain migraine types. For example, in September 2024, the Australian Institute of Health and Welfare, a government agency based in Australia, reported that approximately 411,100 Australians were living with dementia in 2023, a figure projected to more than double by 2058. Consequently, the rising prevalence of neurological disorders is fueling demand for vagus nerve stimulation therapies.

Leading companies in the vagus nerve stimulation market are increasingly concentrating on the introduction of advanced therapeutic solutions, including implantable pulse generators (IPGs), designed to deliver long-term, customizable, and precise treatment for chronic conditions. An implantable pulse generator is a surgically implanted medical device that emits electrical pulses to targeted areas of the body to manage chronic pain or neurological disorders. For instance, in February 2023, LivaNova Plc, a medical device company headquartered in the UK, introduced the SenTiva DUO. This specialized IPG was developed for vagus nerve stimulation therapy, specifically targeting patients with drug-resistant epilepsy. The SenTiva DUO enables individuals with existing dual-pin systems to upgrade without the need for lead replacement, offering enhanced therapy through customizable and automated stimulation delivery. This advancement improves seizure management and supports better treatment adherence, representing a notable improvement in epilepsy care.

In June 2023, SCREEN Holdings Co. Ltd., a Japan-based semiconductor company, acquired an equity stake in Adriakaim Inc. for an undisclosed sum. Through this acquisition, SCREEN aims to work closely with Adriakaim to accelerate the commercialization of its vagus nerve stimulation device. The collaboration also aligns with SCREEN’s broader objective of addressing diverse requirements within the healthcare sector and contributing to solutions for various societal challenges. Adriakaim Inc. is a Japan-based company specializing in the manufacturing of vagus nerve stimulation devices.

Major companies operating in the vagus nerve stimulation market are Medtronic PLC, Boston Scientific Corporation, LivaNova LLC, electroCore Inc., Soterix Medical Inc., Cleveland Medical Devices Inc., MicroTransponder Inc., Parasym Ltd., Neuvana LLC, NeuroSigma Inc., Evren Technologies Inc., Aucta Technologies Inc., SetPoint Medical Corporation, NEMOS GmbH, tVNS Technologies GmbH, Innervate Inc., Neuroelectrics Barcelona S.L., Brainstem Biometrics Inc., BioControl Medical Ltd., Cala Health Inc.

North America was the largest region in the vagus nerve stimulation market in 2025. The regions covered in the vagus nerve stimulation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vagus nerve stimulation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the vagus nerve stimulation market by increasing costs of imported electronic components, microcontrollers, batteries, implantable materials, and stimulation leads used in VNS devices. Neurology clinics and hospitals in North America and Europe are most affected due to reliance on imported device components, while Asia-Pacific faces higher manufacturing and export costs. These tariffs are raising device prices and slowing adoption in cost-sensitive healthcare settings. However, they are also supporting domestic device assembly, regional electronics sourcing, and innovation in cost-optimized neuromodulation solutions.

The vagus nerve stimulation market research report is one of a series of new reports that provides vagus nerve stimulation market statistics, including vagus nerve stimulation industry global market size, regional shares, competitors with a vagus nerve stimulation market share, detailed vagus nerve stimulation market segments, market trends and opportunities, and any further data you may need to thrive in the vagus nerve stimulation industry. This vagus nerve stimulation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Vagus nerve stimulation (VNS) is a medical therapy that delivers electrical impulses to the vagus nerve, a key nerve extending from the brainstem to the abdomen, which regulates functions such as heart rate, digestion, and mood. VNS is primarily used to manage conditions like epilepsy, treatment-resistant depression, and other neurological disorders.

The main products in vagus nerve stimulation include implantable and external VNS devices. Implantable VNS devices are surgically placed, typically in the neck, to deliver electrical impulses to the vagus nerve and treat conditions such as epilepsy and depression. These devices are made from a range of biomaterials, including metals, ceramics, and polymers, and are applied for managing epilepsy, depression, and migraines. Key end-users include hospitals, neurology clinics, ambulatory surgical centers, and research centers.

The vagus nerve stimulation market consists of sales of non-invasive VNS devices, stimulation generators, lead wires and electrodes, rechargeable VNS devices and wearable VNS patches. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.